A Phase 3 interventional study of Rosuvastatin in Carotid Artery Stenosis and Hypercholesterolemia, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-16.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to examine the changes in the carotid artery when subjects receive high or low doses of rosuvastatin.
368 studies on the registry are indexed under Carotid Stenosis; 87 are open to participants now.
This study's planned enrollment of 200 is above the median of 102 across 192 interventional studies indexed under Carotid Stenosis.
Browse Carotid Stenosis studies →AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Rosuvastatin
Also known as: Crestor
Changes in carotid wall volume as measured by MRI scan
Time frame: At 40 weeks and 104 weeks
Safety: adverse events & abnormal laboratory markers
Time frame: 2 weekly for first 4 weeks then 4 weekly
Other changes in the structure and composition of the carotid arterial wall as defined in the protocol.
Time frame: At 40 weeks and 104 weeks
No study locations are listed for this record.
The record gives a start of Jan 2000 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin